January 23, 2014
Novartis Pharma may have been involved in the drafting of the protocol for the investigator-initiated trial “Sign” on its chronic myeloid leukemia (CML) drug Tasigna (nilotinib), Jiho learned from several sources. It is suspected that the Japan unit of Swiss...read more